Pulsemedica 获冠军后CEO采访视频2026年3月12日
https://www.linkedin.com/posts/hans-joerg-fankhauser_healthtech-healthtechglobalsummit-medtech-activity-7437750510012575744-8cJY?utm_source=share&utm_medium=member_android&rcm=ACoAAFQ4M60Bv-RmBfPmi30cHiAH2VDvfAoabfA我们达到了一个重要的成就点，就是在今年完成首次人体治疗实验。我们目前已经投入了五年的工作，再有两到三年内可实现商业化。 加油 牛逼 Pulse Medic Startup Award Sharing
Speaker 1: Congratulations! You just won the startup competition here at the health tech with your startup company. Please share with us a little bit more about Pulse Medic.
Speaker 2: Yeah, thank you. First of all, we're super excited for winning. We came all the way from Edmonton in Canada to this event, and so grateful to be here and to win. So, Pulse Medic, we're building a medical device to treat eye disease, and specifically we're treating an eye disease that's called eye floaters. I know in some languages it's called eye flies. When you look at a bright screen, you see those black dots or lines in your vision that float around—so that's what those are. And those impact about 50% of adults, and 10% of those who have floaters actually have severe floaters. And we're the first to build a treatment for that, and the way it works is it's an image-guided laser treatment system. So essentially we image the floater, and then we're lasering them in the back of the eye.
Speaker 1: How quickly can you help a patient? How far are you in your startup journey?
Speaker 2: Yeah, so first of all, we've already imaged about 250 patients to date, and that's for the purpose of actually understanding what floaters look like and all that. On the treatment side, actually this year is a very exciting year, because we're moving towards our first in-human treatment. So that'll be a first clinical study with the treatment system, and we've worked about 5 years to get to this stage. And that's very exciting. We are still 2 to 3 years away past that to get to commercialization.
Speaker 3: There are some challenges that exist of course as we think about AI. You know, for us, we're using a diagnostic assist, right? So there are some elements that we're allowed to essentially train our data on real patient imaging, right? So we're planning on pursuing that regulatory pathway in Canada, and in North America generally in the next couple years. So, very excited about that opportunity.
Speaker 1: We're here in Balsall, surrounded by life science, surrounded by projects like Uptown Balsall. It's a big connection to AI, to quantum also. Is it kind of also an inspiration for you to maybe be here in this surrounding?
Speaker 3: Yes, absolutely. It's been amazing this whole event in the last two days. We weren't exactly sure what to expect given we're from Canada, haven't been to this part of the world before, but the event has been fantastic. The connections and networking—we just continue to be amazed by the connections and the people here. So it's been awesome.
pm团队有没有发相关的论文？比如他们的动物实验结果是什么？有没有论文描述一下他们的结果？ sun1992 发表于 2026-3-13 10:58
Pulse Medic Startup Award Sharing
Speaker 1: Congratulations! You just won the startup competition ...
I know in some languages it's called eye flies.
不知道这句是否指的是中文的飞蚊 sun1992 发表于 2026-3-13 10:58
Pulse Medic Startup Award Sharing
Speaker 1: Congratulations! You just won the startup competition ...
字幕应该是后期修正过的吧，因为如果直接识别的话，加拿大人的英语里总会有很多eh（笑） reddit 网友在领英上找到的一张图 PulseMedica 在这个展会上的一页 PPT，疑似是激光在眼球里的工作范围 也就是说pm两到三年就可以用到了吗
ag47 发表于 2026-3-13 22:27
reddit 网友在领英上找到的一张图 PulseMedica 在这个展会上的一页 PPT，疑似是激光在眼球里的工作范围 ...
这就是个示意图，表明可用于很大范围的治疗。
CEO的演讲展示介绍，原文如下
PulseMedica is pioneering ophthalmic laser surgery with the world’s first image-guided #femtosecond laser platform designed to image, diagnose, and treat anywhere in the eye. Its lead clinical application targets symptomatic vitreous opacities (floaters), a major unmet need in ophthalmology. Our platform combines 3D imaging, AI-driven targeting, and automated femtosecond lasertreatment patterns throughout the vitreous.
明确写到可以治疗玻璃体的任何部位。我认为理论上和实验室都是可以做到的，但目前为了符合各国的安全规范，设定了一个最小距离。随着后续发展，最后能实现整个玻璃体的治疗。
页:
[1]
2